Elixcyte is under clinical development by Unicocell Biomed and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elixcyte’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elixcyte overview
Elixcyte is under development for the treatment of chronic kidney disease, chronic wounds, retinal degeneration and knee osteoarthritis. It is administered intravenous and intraarticular routes. The drug candidate is an allogeneic adipose stem cell product.
Unicocell Biomed overview
Unicocell Biomed is a medical care, research and healthcare service provider. The company offers products that include stem cells and stem cell secretions, beauty care products, medical materials, injections and medicament, healthcare products and skin care products, among others. Unicocell Biomed offers services include new drug development services, new medical research services, stem cell applications research services, new technology development services, clinical trials, research and development, beauty and slimming services, medical equipment leasing services, stem cell services and others. Its stem cell applications research services include stem cell introduction, stem cell application and stem cell storage and safety declaration services. Unicocell Biomed is headquartered in Taipei, Taiwan.
For a complete picture of Elixcyte’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
